|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TMEM25 |
Gene summary for TMEM25 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TMEM25 | Gene ID | 84866 |
| Gene name | transmembrane protein 25 | |
| Gene Alias | TMEM25 | |
| Cytomap | 11q23.3 | |
| Gene Type | protein-coding | GO ID | GO:0003008 | UniProtAcc | Q86YD3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 84866 | TMEM25 | LZE4T | Human | Esophagus | ESCC | 2.32e-04 | 1.37e-01 | 0.0811 |
| 84866 | TMEM25 | LZE22T | Human | Esophagus | ESCC | 2.36e-07 | 6.38e-01 | 0.068 |
| 84866 | TMEM25 | LZE24T | Human | Esophagus | ESCC | 2.44e-11 | 3.13e-01 | 0.0596 |
| 84866 | TMEM25 | P2T-E | Human | Esophagus | ESCC | 7.77e-17 | 2.35e-01 | 0.1177 |
| 84866 | TMEM25 | P4T-E | Human | Esophagus | ESCC | 9.35e-18 | 4.19e-01 | 0.1323 |
| 84866 | TMEM25 | P5T-E | Human | Esophagus | ESCC | 4.68e-11 | 1.77e-01 | 0.1327 |
| 84866 | TMEM25 | P8T-E | Human | Esophagus | ESCC | 1.55e-10 | 2.36e-01 | 0.0889 |
| 84866 | TMEM25 | P9T-E | Human | Esophagus | ESCC | 1.27e-07 | 1.27e-01 | 0.1131 |
| 84866 | TMEM25 | P10T-E | Human | Esophagus | ESCC | 2.46e-17 | 3.60e-01 | 0.116 |
| 84866 | TMEM25 | P11T-E | Human | Esophagus | ESCC | 1.87e-15 | 6.49e-01 | 0.1426 |
| 84866 | TMEM25 | P12T-E | Human | Esophagus | ESCC | 5.62e-30 | 4.52e-01 | 0.1122 |
| 84866 | TMEM25 | P15T-E | Human | Esophagus | ESCC | 3.44e-04 | 1.22e-01 | 0.1149 |
| 84866 | TMEM25 | P16T-E | Human | Esophagus | ESCC | 3.65e-28 | 5.04e-01 | 0.1153 |
| 84866 | TMEM25 | P17T-E | Human | Esophagus | ESCC | 1.47e-03 | 2.64e-01 | 0.1278 |
| 84866 | TMEM25 | P21T-E | Human | Esophagus | ESCC | 1.47e-34 | 6.55e-01 | 0.1617 |
| 84866 | TMEM25 | P22T-E | Human | Esophagus | ESCC | 1.14e-14 | 2.86e-01 | 0.1236 |
| 84866 | TMEM25 | P24T-E | Human | Esophagus | ESCC | 2.17e-08 | 1.43e-01 | 0.1287 |
| 84866 | TMEM25 | P26T-E | Human | Esophagus | ESCC | 8.63e-21 | 4.25e-01 | 0.1276 |
| 84866 | TMEM25 | P27T-E | Human | Esophagus | ESCC | 1.78e-17 | 2.56e-01 | 0.1055 |
| 84866 | TMEM25 | P28T-E | Human | Esophagus | ESCC | 1.49e-10 | 1.16e-01 | 0.1149 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:190589732 | Oral cavity | NEOLP | regulation of response to endoplasmic reticulum stress | 20/2005 | 82/18723 | 3.21e-04 | 3.11e-03 | 20 |
| GO:007099732 | Oral cavity | NEOLP | neuron death | 60/2005 | 361/18723 | 3.70e-04 | 3.50e-03 | 60 |
| GO:190121431 | Oral cavity | NEOLP | regulation of neuron death | 52/2005 | 319/18723 | 1.37e-03 | 9.77e-03 | 52 |
| GO:190121531 | Oral cavity | NEOLP | negative regulation of neuron death | 36/2005 | 208/18723 | 2.54e-03 | 1.60e-02 | 36 |
| GO:190589831 | Oral cavity | NEOLP | positive regulation of response to endoplasmic reticulum stress | 10/2005 | 35/18723 | 2.88e-03 | 1.77e-02 | 10 |
| GO:00064874 | Prostate | BPH | protein N-linked glycosylation | 21/3107 | 65/18723 | 1.37e-03 | 8.19e-03 | 21 |
| GO:000648712 | Prostate | Tumor | protein N-linked glycosylation | 23/3246 | 65/18723 | 3.63e-04 | 2.84e-03 | 23 |
| GO:001049828 | Skin | cSCC | proteasomal protein catabolic process | 243/4864 | 490/18723 | 7.85e-30 | 4.10e-27 | 243 |
| GO:004217629 | Skin | cSCC | regulation of protein catabolic process | 198/4864 | 391/18723 | 6.03e-26 | 1.89e-23 | 198 |
| GO:190336229 | Skin | cSCC | regulation of cellular protein catabolic process | 139/4864 | 255/18723 | 2.06e-22 | 4.17e-20 | 139 |
| GO:190305029 | Skin | cSCC | regulation of proteolysis involved in cellular protein catabolic process | 121/4864 | 221/18723 | 6.75e-20 | 1.01e-17 | 121 |
| GO:006113629 | Skin | cSCC | regulation of proteasomal protein catabolic process | 106/4864 | 187/18723 | 4.31e-19 | 5.87e-17 | 106 |
| GO:0034976112 | Skin | cSCC | response to endoplasmic reticulum stress | 128/4864 | 256/18723 | 1.16e-16 | 1.17e-14 | 128 |
| GO:004586229 | Skin | cSCC | positive regulation of proteolysis | 169/4864 | 372/18723 | 2.43e-16 | 2.21e-14 | 169 |
| GO:000989628 | Skin | cSCC | positive regulation of catabolic process | 206/4864 | 492/18723 | 6.06e-15 | 4.64e-13 | 206 |
| GO:190336429 | Skin | cSCC | positive regulation of cellular protein catabolic process | 85/4864 | 155/18723 | 1.87e-14 | 1.31e-12 | 85 |
| GO:003133128 | Skin | cSCC | positive regulation of cellular catabolic process | 182/4864 | 427/18723 | 3.29e-14 | 2.22e-12 | 182 |
| GO:004573229 | Skin | cSCC | positive regulation of protein catabolic process | 112/4864 | 231/18723 | 1.37e-13 | 8.40e-12 | 112 |
| GO:190180025 | Skin | cSCC | positive regulation of proteasomal protein catabolic process | 66/4864 | 114/18723 | 5.18e-13 | 3.01e-11 | 66 |
| GO:190305225 | Skin | cSCC | positive regulation of proteolysis involved in cellular protein catabolic process | 72/4864 | 133/18723 | 4.24e-12 | 2.27e-10 | 72 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TMEM25 | deletion | Frame_Shift_Del | novel | c.575delA | p.Asn192ThrfsTer85 | p.N192Tfs*85 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | |||
| TMEM25 | SNV | Missense_Mutation | novel | c.758G>A | p.Ser253Asn | p.S253N | protein_coding | tolerated(0.29) | benign(0.062) | TCGA-C5-A8XK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
| TMEM25 | SNV | Missense_Mutation | rs782188288 | c.145G>A | p.Ala49Thr | p.A49T | protein_coding | tolerated(0.54) | benign(0.207) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| TMEM25 | SNV | Missense_Mutation | c.1033N>T | p.Leu345Phe | p.L345F | protein_coding | tolerated_low_confidence(0.07) | benign(0.015) | TCGA-FU-A3EO-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | ||
| TMEM25 | SNV | Missense_Mutation | novel | c.97N>A | p.Asp33Asn | p.D33N | protein_coding | tolerated(0.2) | probably_damaging(0.998) | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD | |
| TMEM25 | SNV | Missense_Mutation | novel | c.224G>A | p.Ser75Asn | p.S75N | protein_coding | tolerated(0.51) | benign(0.007) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| TMEM25 | SNV | Missense_Mutation | rs377765778 | c.599N>A | p.Arg200His | p.R200H | protein_coding | tolerated(0.3) | benign(0.003) | TCGA-AZ-6598-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TMEM25 | SNV | Missense_Mutation | rs75184401 | c.458C>T | p.Ala153Val | p.A153V | protein_coding | tolerated(0.5) | benign(0.213) | TCGA-AG-3883-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| TMEM25 | deletion | Frame_Shift_Del | c.166delN | p.Pro58LeufsTer23 | p.P58Lfs*23 | protein_coding | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | ||||
| TMEM25 | deletion | Frame_Shift_Del | c.166delN | p.Pro58LeufsTer23 | p.P58Lfs*23 | protein_coding | TCGA-A6-3809-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |